Ioana Braicu

Head of clinical and translational research

Charité - Universitätsmedizin Berlin

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ioana Braicu is the Head of Clinical and Translational Research at Charité - Universitätsmedizin Berlin, Germany. Her research primarily focuses on personalized medicine in oncology, particularly in the context of ovarian and endometrial cancer. Recent publications include work on treatment paradigms for high-grade serous ovarian cancer and practical guidelines for gestational trophoblastic disease. She also investigates the molecular mechanisms of treatment resistance and the role of circadian rhythms in cancer therapy.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (9)

Edgar Petru

Medical University of Graz

AUSTRIA

View details

Angela Relógio

MSH Medical School Hamburg University of Applied Sciences and Medical University

GERMANY

View details

Simon Schallenberg

GERMANY

View details

Christof Vulsteke

University of Antwerp

BELGIUM

View details

isabelle ray coquard

professor

FRANCE

View details

Wenzel Schöning

Charité - Universitätsmedizin Berlin

GERMANY

View details

Sylvia mechsner

charité university hospital

GERMANY

View details

Pawel KORDOWITZKI

Assistant Professor

Nicolaus Copernicus University

POLAND

View details

Christoph Grimm

Medical University of Vienna

AUSTRIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ioana Braicu

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

GANNET53 Part II: A European Phase I/II Trial of the HSP90 Inhibitor Ganetespib in High-Grade Platinum-Resistant Ovarian Cancer—A Study of the GANNET53 Consortium

Transforming treatment paradigms: Focus on personalized medicine for high‐grade serous ovarian cancer

Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Correction: ERRα promotes glycolytic metabolism and targets the NLRP3/caspase-1/GSDMD pathway to regulate pyroptosis in endometrial cancer.

Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients.

Intergroup-statement: statement of the german ovarian cancer commission, the North-Eastern German Society of gynecological Oncology (NOGGO), AGO Austria and AGO Swiss regarding the use of homologous repair deficiency (HRD) assays in advanced ovarian cancer.

Mucinous cystic neoplasms of the pancreas and liver share a similar DNA methylation profile with mucinous ovarian tumors.

Reproducibility of positive AGO score in predicting complete cytoreduction in recurrent low-grade ovarian cancers.

Collaborators (9)

Edgar Petru

Angela Relógio

Simon Schallenberg

Christof Vulsteke

isabelle ray coquard

Wenzel Schöning

Sylvia mechsner

Pawel KORDOWITZKI

Christoph Grimm

Make your next move.